FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207368002> ?p ?o ?g. }

• W3207368002 endingPage "543" @default.
• W3207368002 startingPage "532" @default.
• W3207368002 abstract "It is unestablished whether andexanet alfa, compared with guideline-based usual care including prothrombin complex concentrates, is associated with reduced hematoma expansion (HE) and mortality in patients with factor-Xa inhibitor-related intracerebral hemorrhage (ICH). We compared the occurrence of HE and clinical outcomes in patients treated either with andexanet alfa or with usual care during the acute phase of factor-Xa inhibitor-related ICH.Data were extracted from the multicenter, prospective, single-arm ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) and a multicenter observational cohort study, RETRACE-II (German-Wide Multicenter Analysis of Oral Anticoagulant-Associated Intracerebral Hemorrhage - Part Two). HE was based on computed tomography scans performed within 36 hours from baseline imaging. Inverse probability of treatment weighting was performed to adjust for baseline comorbidities and ICH severity. Patients presenting with atraumatic ICH while receiving apixaban or rivaroxaban within 18 hours of admission were included. Patients with secondary ICH or not fulfilling the inclusion criteria for the ANNEXA-4 trial were excluded. We compared ANNEXA-4 patients, who received andexanet alfa for hemostatic treatment, with RETRACE-II patients who were treated with usual care, primarily administration of prothrombin complex concentrates. Primary outcome was rate of HE defined as relative increase of ≥35%. Secondary outcomes comprised mean absolute change in hematoma volume, as well as in-hospital mortality and functional outcome.Overall, 182 patients with factor-Xa inhibitor-related ICH (85 receiving andexanet alfa versus 97 receiving usual care) were selected for analysis. There were no relevant differences regarding demographic or clinical characteristics between both groups. HE occurred in 11 of 80 (14%) andexanet alfa patients compared with 21 of 67 (36%) usual care patients (adjusted relative risk, 0.40 [95% CI, 0.20-0.78]; P=0.005), with a reduction in mean overall hematoma volume change of 7 mL. There were no statistically significant differences among in-hospital mortality or functional outcomes. Sensitivity analysis including only usual care patients receiving prothrombin complex concentrates demonstrated consistent results.As compared with usual care, andexanet alfa was associated with a lower rate of HE in atraumatic factor-Xa inhibitor-related ICH, however, without translating into significantly improved clinical outcomes. A comparative trial is needed to confirm the benefit on limiting HE and to explore clinical outcomes across patient subgroups and by time to treatment. Registration: URL: https://clinicaltrials.gov; Unique identifier: NCT02329327 and NCT03093233." @default.
• W3207368002 created "2021-10-25" @default.
• W3207368002 creator A5000654664 @default.
• W3207368002 creator A5000735539 @default.
• W3207368002 creator A5003238210 @default.
• W3207368002 creator A5003777168 @default.
• W3207368002 creator A5004003194 @default.
• W3207368002 creator A5010877279 @default.
• W3207368002 creator A5012372014 @default.
• W3207368002 creator A5014149325 @default.
• W3207368002 creator A5015513362 @default.
• W3207368002 creator A5020373936 @default.
• W3207368002 creator A5046643965 @default.
• W3207368002 creator A5053228230 @default.
• W3207368002 creator A5055320315 @default.
• W3207368002 creator A5079046512 @default.
• W3207368002 date "2022-02-01" @default.
• W3207368002 modified "2023-10-15" @default.
• W3207368002 title "Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care" @default.
• W3207368002 cites W1964182391 @default.
• W3207368002 cites W2009187570 @default.
• W3207368002 cites W2034607173 @default.
• W3207368002 cites W2037668591 @default.
• W3207368002 cites W2048565444 @default.
• W3207368002 cites W2094585602 @default.
• W3207368002 cites W2100677075 @default.
• W3207368002 cites W2105908213 @default.
• W3207368002 cites W2110818436 @default.
• W3207368002 cites W2129241155 @default.
• W3207368002 cites W2134070683 @default.
• W3207368002 cites W2152623033 @default.
• W3207368002 cites W2153134011 @default.
• W3207368002 cites W2155070090 @default.
• W3207368002 cites W2168458505 @default.
• W3207368002 cites W2214011890 @default.
• W3207368002 cites W2330133051 @default.
• W3207368002 cites W2409181187 @default.
• W3207368002 cites W2575790444 @default.
• W3207368002 cites W2604517925 @default.
• W3207368002 cites W2734827407 @default.
• W3207368002 cites W2747775477 @default.
• W3207368002 cites W2781949590 @default.
• W3207368002 cites W2787493763 @default.
• W3207368002 cites W2804714053 @default.
• W3207368002 cites W2908990133 @default.
• W3207368002 cites W2914368780 @default.
• W3207368002 cites W2914381505 @default.
• W3207368002 cites W2932976565 @default.
• W3207368002 cites W2946210002 @default.
• W3207368002 cites W2946701789 @default.
• W3207368002 cites W2987636674 @default.
• W3207368002 cites W3000879818 @default.
• W3207368002 cites W3012047724 @default.
• W3207368002 cites W3014238593 @default.
• W3207368002 cites W3015446292 @default.
• W3207368002 cites W3039232825 @default.
• W3207368002 cites W3095633432 @default.
• W3207368002 cites W3120244688 @default.
• W3207368002 doi "https://doi.org/10.1161/strokeaha.121.034572" @default.
• W3207368002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34645283" @default.
• W3207368002 hasPublicationYear "2022" @default.
• W3207368002 type Work @default.
• W3207368002 sameAs 3207368002 @default.
• W3207368002 citedByCount "21" @default.
• W3207368002 countsByYear W32073680022022 @default.
• W3207368002 countsByYear W32073680022023 @default.
• W3207368002 crossrefType "journal-article" @default.
• W3207368002 hasAuthorship W3207368002A5000654664 @default.
• W3207368002 hasAuthorship W3207368002A5000735539 @default.
• W3207368002 hasAuthorship W3207368002A5003238210 @default.
• W3207368002 hasAuthorship W3207368002A5003777168 @default.
• W3207368002 hasAuthorship W3207368002A5004003194 @default.
• W3207368002 hasAuthorship W3207368002A5010877279 @default.
• W3207368002 hasAuthorship W3207368002A5012372014 @default.
• W3207368002 hasAuthorship W3207368002A5014149325 @default.
• W3207368002 hasAuthorship W3207368002A5015513362 @default.
• W3207368002 hasAuthorship W3207368002A5020373936 @default.
• W3207368002 hasAuthorship W3207368002A5046643965 @default.
• W3207368002 hasAuthorship W3207368002A5053228230 @default.
• W3207368002 hasAuthorship W3207368002A5055320315 @default.
• W3207368002 hasAuthorship W3207368002A5079046512 @default.
• W3207368002 hasBestOaLocation W32073680021 @default.
• W3207368002 hasConcept C126322002 @default.
• W3207368002 hasConcept C127413603 @default.
• W3207368002 hasConcept C141071460 @default.
• W3207368002 hasConcept C168563851 @default.
• W3207368002 hasConcept C2775965419 @default.
• W3207368002 hasConcept C2776301958 @default.
• W3207368002 hasConcept C2777091921 @default.
• W3207368002 hasConcept C2777094939 @default.
• W3207368002 hasConcept C2777736543 @default.
• W3207368002 hasConcept C2778205648 @default.
• W3207368002 hasConcept C2778661090 @default.
• W3207368002 hasConcept C2779161974 @default.
• W3207368002 hasConcept C2779662492 @default.
• W3207368002 hasConcept C2780638905 @default.
• W3207368002 hasConcept C2780645631 @default.
• W3207368002 hasConcept C2992435398 @default.

• next